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a  b  s  t  r  a  c  t
INTRODUCTION:  Clostridium  difficile  is the most  common  cause  of healthcare-associated  infections  and
can have  devastating  morbidity  and  mortality.  Traditional  treatment  algorithms  involve  intravenous
metronidazole  and  enteric  metronidazole  or vancomycin.  Fidaxomicin  (DificidR) targets  “switch  regions”
within RNA  polymerases  and effectively  kills  clostridium  difficile  bacteria  and is typically  administered
orally  primarily  or through  a naso/oro-gastric  conduit.
PRESENTATION  OF  CASE:  55-year-old  with  a recent  elective  surgical  procedure  was  hospitalized  with
multifocal  pneumonia  and  subsequently  developed  clostridium  difficile  colitis.  This  patient  failed  the
standard  medical  therapy  for clostridium  difficile  colitis,  decompensated  and  required  surgical  explo-
ration, partial  colectomy  and  mucous  fistula  creation.  Following  her surgery,  her  clinical  condition
improved  and  her colitis  resolved  with  the antegrade  administration  of fidaxomicin  through  her  mucous
fistula.
DISCUSSION:  Fidaxomicin  is  a newer  to market  therapeutic  agent  that has  been  shown  to be effective  in
the  treatment  of clostridium  difficile  colitis.  Previously  studies  have  shown  benefit  of  oral  fidaxomicin
therapy  for  fulminant  clostridium  difficile  but  our  study  case  report  describes  the  index case  of  topical
fidaxomicin  through  a  mucous  fistula.
CONCLUSION:  In our  case  of  fulminant  clostridium  difficile  colitis,  Fidaxomicin  administered  in an  ante-
grade  fashion  through  a mucous  fistula  may  have  reduced  the  need  for total colectomy  in the  treatment
of  fulminant  clostridium  difficile  colitis.
©  2017  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Clostridium difficile (CD) is the most common cause of
healthcare-associated infections with over half a million cases
in the United States each year [1]. Oral fidaxomicin (DificidR)
was approved by the FDA for the treatment of CD in 2011
and, in comparison to rectal vancomycin [2,3], it targets “switch
regions” within bacterial RNA polymerases. Fidaxomicin has been
shown to effectively neutralizes CD species producing symptomatic
cure and reduced recurrence. We  present a case of fulminant
CD colitis following treatment for hospital acquired multifocal
pneumonia ultimately requiring an exploratory laparotomy and
segmental colectomy. Following segmental colectomy, the patient
was successfully treated with 10 days of antegrade fidaxomicin
∗ Corresponding author at: General Surgery Resident George Washington Uni-
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administered through the mucus fistula with subsequent stool
polymerase chain reaction (PCR) testing showing remission of dis-
ease. The work in this case has been reported in line with the SCARE
criteria [4].
2. Case report
A 55-year-old woman  with a past medical history of hyperten-
sion, diabetes mellitus, prior transient ischemic attacks, and chronic
kidney disease was admitted to the ICU for altered mental status
after being found minimally responsive at home four postoperative
days following an elective panniculectomy. Her initial workup was
significant for a multi-focal pneumonia with concomitant acute
kidney injury requiring initiation of hemodialysis. She was ini-
tially started on broad spectrum gram positive (vancomycin) and
gram negative (piperacillin-tazobactam) coverage but on hospital
day ten developed new onset watery diarrhea. Stool PCR testing
was positive for CD and the patient was  started on intravenous
metronidazole (500 mg  IV every six hours) and oral vancomycin
(250 mg  every six hours). After six days and despite double ther-
https://doi.org/10.1016/j.ijscr.2017.11.042
2210-2612/© 2017 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Matured end ileostomy (A) and mucous fistula (B) following segmental right colectomy for fulminant clostridium difficile colitis. Note the presence of continued
pseudomembranous disease on the mucous fistula prior to administration of antegrade fidaxomicin.
apy, the patient’s disease progressed to fulminant CD colitis with
advanced imaging showing pancolitis without evidence of mega-
colon or perforation. Rectal vancomycin (500 mg  every six hours)
and oral fidaxomicin (200 mg  twice daily) were added however
within two days the patient had decompensated, her leukocytosis
had progressed to 54,000/ul, and she required multiple vasoac-
tive medications to sustain a mean arterial pressure greater than
65 mmHg. The decision was made to proceed to the operating room
for laparotomy and subtotal colectomy with an end ileostomy. The
procedure was performed by a general surgeon with more than
twenty years of experience with critical care surgery.
During laparotomy, the right colon appeared edematous with
evidence of significant inflammation with a transition point to
healthy appearing colon distal to the hepatic flexure. Similarly, the
small bowel appeared healthy proximal to the ileocecal valve. The
ascending colon and small bowel extending 10 cm proximal to the
ileocecal valve were resected leaving the patient in enteric disconti-
nuity. The abdomen was then irrigated and a temporary abdominal
closure vacuum dressing was placed and the patient was taken
back to the ICU for continued resuscitation. While in the operating
room, the resected colon and small bowel were opened on the back
table revealing a significant burden of pseudomembranous disease
within the ascending colon. Postoperative pathological analysis of
the resected colon and small bowel confirmed our clinical suspi-
cions identifying acute enterocolitis with transmural inflammation
and luminal pseudo-membrane formation.
The patient remained hemodynamically stable overnight and
was taken back to the operating room the following day for re-
evaluation of the abdomen and potential abdominal closure. On
second look, the terminal ileum and transverse colon appeared
healthy without progression of clinical colitis. The terminal ileum
and transverse colon stumps were externalized and matured fol-
lowing successful primary fascia closure (Fig. 1). Following the
second operation, the mucus fistula developed new pseudomem-
branes consistent with persistent colitis. Over ten days, crushed
fidaxomicin (200 mg  twice daily) was administered through the
mucous fistula by a red-rubber catheter in an antegrade fashion.
During the ten-day course of antegrade fidaxomicin, the clini-
cal burden of pseudomembranous disease on the mucous fistula
receded, hemodynamic lability improved, and the leukocytosis
cleared. Upon completion of the ten-day course of antegrade fidax-
omicin by mucous fistula, repeat stool CD PCR studies from the
mucous fistula were negative for CD.
3. Discussion
Over the last decade, there has been a notable increase in the
severity of CD infections in addition to the discovery of new vir-
ulent strains [5]. With the high incidence and increased severity,
the literature has proposed multiple new agents and strategies for
managing CD infections that have failed to improve with metron-
idazole and vancomycin treatment alone [6]. Fidaxomicin was
approved by the FDA for the treatment of CD in 2011 after it was
shown to be non-inferior to rectal vancomycin in two large ran-
domized controlled trials [7,8]. While most of these initial patients
only had mild to moderate illness, fidaxomicin has proven efficacy
for symptomatic cure in addition to reducing disease recurrence
compared to rectal vancomycin [3]. As a result, despite the higher
cost of fidaxomicin, it has gained significant popularity for compli-
cated CD infections [9].
Fidaxomicin is currently FDA approved for oral administration
and has been demonstrated to have a 98–100% recovery when
crushed and dispersed into various liquid vehicles [10]. Further-
more, multiple case reports have demonstrated successful medical
management of severe CD colitis with crushed fidaxomicin through
a nasogastric tube [11,12]. Since CD colitis is a toxin mediated dis-
ease, postoperative antibiotics are usually also recommended even
in the cases of subtotal colectomy which should in theory provide
mechanical source control [13]. Given the morbidity of a subtotal
colectomy, there has recently been a push towards bowel spar-
ing treatment regimens, most notably being loop ileostomy with
intraoperative colonic lavage and 10 days of vancomycin antegrade
washes [14].
While the initial administration of oral fidaxomicin in this case
did not prevent the need for surgical intervention, it is possible
that doses prior to surgery had not reached the affected colon sec-
ondary to the ileus from the patient’s inflammatory state. Following
segmental resection, topical administration of fidaxomicin was
possible, bypassing any prior absorption or transit issues with oral
administration. Topical application of fidaxomicin has rarely been
described in patients with severe disease requiring bowel resec-
tion. One prior case in the Czech Republic was described by Longin
et al. where topical fidaxomicin 200 mg  in small volume enemas
was started after the patient failed to improve with metronidazole
and vancomycin for eleven days after bowel resection. This patient
eventually tested negative for CD by NAAT amplification and had
successful gastrointestinal tract restoration after five months [15].
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In this case, our patient failed to improve with intravenous
metronidazole and rectal vancomycin alone, prompting the addi-
tion of oral fidaxomicin as a third agent for CD treatment. However,
when the patient became hypotensive and refractory to resuscita-
tion, surgical intervention was required. After the creation of her
end-ileostomy and mucus fistula, crushed fidaxomicin successfully
supplemented enteric vancomycin resulting in symptomatic and
bacteriologic cure. This case report demonstrates a new admin-
istration route for fidaxomicin through mucous fistula that may
prove effective in curing fulminant CD colitis obviating the need
for subtotal colectomy.
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